Literature DB >> 32956754

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.

Lokeswari P Tangella1, Michael E Clark1, Elin S Gray2.   

Abstract

BACKGROUND: The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have improved survival rates in a significant proportion of patients. Nonetheless, the emergence of resistance to treatment remains inevitable in most patients. SCOPE OF REVIEW: Here, we review known and emerging molecular mechanisms that underlay the development of resistance to MAPK inhibition in melanoma cells and the potential strategies to overcome these mechanisms. MAJOR
CONCLUSIONS: Multiple genetic and non-genetic mechanisms contribute to treatment failure, commonly leading to the reactivation of the MAPK pathway. A variety of resistance mechanisms are enabled by the underlying heterogeneity and plasticity of melanoma cells. Moreover, it has become apparent that resistance to targeted therapy is underpinned by early functional adaptations involving the rewiring of cell states and metabolic pathways. GENERAL SIGNIFICANCE: The evidence presented suggest that the use of a combinatorial treatment approach would delay the emergence of resistance and improve patient outcomes.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Acquired resistance; Intrinsic resistance; Metabolic reprogramming; Targeted therapy; Tumour adaptations; Tumour plasticity

Mesh:

Substances:

Year:  2020        PMID: 32956754     DOI: 10.1016/j.bbagen.2020.129736

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  10 in total

1.  Nuclear interaction of Arp2/3 complex and BRAFV600E promotes aggressive behavior and vemurafenib resistance of thyroid cancer.

Authors:  Mourad Zerfaoui; Koji Tsumagari; Eman Toraih; Youssef Errami; Emmanuelle Ruiz; Mohammed Sohail M Elaasar; Moroz Krzysztof; Andrew B Sholl; Sameh Magdeldin; Mohamed Soudy; Zakaria Y Abd Elmageed; A Hamid Boulares; Emad Kandil
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches.

Authors:  Claudio Tabolacci; Martina Cordella; Stefania Rossi; Marialaura Bonaccio; Adriana Eramo; Carlo Mischiati; Simone Beninati; Licia Iacoviello; Antonio Facchiano; Francesco Facchiano
Journal:  Molecules       Date:  2021-06-13       Impact factor: 4.411

3.  Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.

Authors:  Andrew J Kavran; Scott A Stuart; Kristyn R Hayashi; Joel M Basken; Barbara J Brandhuber; Natalie G Ahn
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-15       Impact factor: 12.779

Review 4.  Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.

Authors:  Elena-Georgiana Dobre; Carolina Constantin; Monica Neagu
Journal:  J Pers Med       Date:  2022-07-13

5.  Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma.

Authors:  Jing Yu; Xi Wu; Jinen Song; Yujie Zhao; Huifang Li; Min Luo; Xiaowei Liu
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

6.  Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach.

Authors:  Cristina Catoni; Cristina Poggiana; Antonella Facchinetti; Jacopo Pigozzo; Luisa Piccin; Vanna Chiarion-Sileni; Antonio Rosato; Giovanni Minervini; Maria Chiara Scaini
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

7.  Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway.

Authors:  Lei Wang; Wuxiyar Otkur; Aman Wang; Wen Wang; Yitong Lyu; Lei Fang; Xiu Shan; Mingzhou Song; Yan Feng; Yi Zhao; Hai-Long Piao; Huan Qi; Ji-Wei Liu
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

Review 8.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

9.  Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.

Authors:  Valentina Audrito; Enrico Moiso; Filippo Ugolini; Vincenzo Gianluca Messana; Lorenzo Brandimarte; Ilaria Manfredonia; Simonetta Bianchi; Francesco De Logu; Romina Nassini; Anna Szumera-Ciećkiewicz; Daniela Taverna; Daniela Massi; Silvia Deaglio
Journal:  J Transl Med       Date:  2022-03-10       Impact factor: 5.531

10.  The human melanoma proteome atlas-Defining the molecular pathology.

Authors:  Lazaro Hiram Betancourt; Jeovanis Gil; Yonghyo Kim; Viktória Doma; Uğur Çakır; Aniel Sanchez; Jimmy Rodriguez Murillo; Magdalena Kuras; Indira Pla Parada; Yutaka Sugihara; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Erika Velasquez; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Krzysztof Pawłowski; Jonatan Eriksson; Beáta Szeitz; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Runyu Hong; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Qimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Peter Horvath; Leticia Szadai; József Tímár; Sarolta Kárpáti; A Marcell Szász; Johan Malm; David Fenyö; Henrik Ekedahl; István Balázs Németh; György Marko-Varga
Journal:  Clin Transl Med       Date:  2021-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.